Skip to Content
Merck
CN

SML1942

Drotaverine hydrochloride

≥95% (HPLC), powder, PDE inhibitor

Synonym(s):

1-[(3,4-Diethoxyphenyl)methylene]-6,7-diethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride, 3′,4′,6,7-Tetraethoxy-1-benzylidene-1,2,3,4-tetrahydroisoquinoline hydrochloride, Drotaverin hydrochloride, Tetraspasmin-Lefa

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C24H31NO4 · HCl
CAS Number:
985-12-6
Molecular Weight:
433.97
NACRES:
NA.77
UNSPSC Code:
12352200
MDL number:
MFCD00347721
Assay:
≥95% (HPLC)
Form:
powder
Quality level:
100
Storage condition:
desiccated

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Drotaverine hydrochloride, ≥95% (HPLC)

InChI

1S/C24H31NO4.ClH/c1-5-26-21-10-9-17(14-22(21)27-6-2)13-20-19-16-24(29-8-4)23(28-7-3)15-18(19)11-12-25-20;/h9-10,13-16,25H,5-8,11-12H2,1-4H3;1H/b20-13-;

SMILES string

CCOC1=CC=C(/C=C2C3=C(CCN/2)C=C(OCC)C(OCC)=C3)C=C1OCC.[H]Cl

InChI key

JBFLYOLJRKJYNV-MASIZSFYSA-N

assay

≥95% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: 2 mg/mL, clear (warmed)

storage temp.

2-8°C

Quality Level

100

Related Categories

Biochem/physiol Actions

A PDE4-selective phosphodiesterase inhibitor and an L-type voltage-dependent calcium channel blocker with in vivo antispasmodic efficacy.
Drotaverine (Drotaverin) is an isoquinoline-based PDE4-selective phosphodiesterase (PDE) inhibitor and an L-type voltage-dependent (voltage-operated) calcium channel (L-VDCC or L-VOCC) blocker that exhibits in vivo antispasmodic efficacy without anticholinergic effects.
It is a benzylisoquinoline derivative. Drotaverine acts as a smooth muscle relaxant.

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000525302
0000525302
0000441477
0000441477
0000437290

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

A G Stepaniuk et al.
Eksperimental'naia i klinicheskaia farmakologiia, 61(4), 17-19 (1998-10-23)
The study was conducted on experimental models of pain sense induced in mice by exposure to thermic or chemical factors and in rats by exposure to electric factors. Nitrosorbide and no-spa possess a dose-dependent analgesic effect. Both drugs excelled analgin
Corradini D, et al.
Handbook of HPLC (2011)
Zsuzsanna Tömösközi et al.
European journal of pharmacology, 449(1-2), 55-60 (2002-08-07)
The effect of the isoquinoline derivative, drotaverine on the specific binding of [(3)H]nitrendipine and [(3)H]diltiazem to pregnant rat uterine membranes was examined. Drotaverine inhibited the specific [(3)H]nitrendipine and [(3)H]diltiazem bindings with IC(50) values of 5.6 and 2.6 microM, respectively. Saturation
Zoltán Patai et al.
The Journal of pharmacology and experimental therapeutics, 359(3), 442-451 (2016-10-16)
Drotaverine is considered an inhibitor of cyclic-3',5'-nucleotide-phophodiesterase (PDE) enzymes; however, published receptor binding data also support the potential L-type voltage- operated calcium channel (L-VOCC) blocking effect of drotaverine. Hence, in this work, we focus on the potential L-VOCC blocking effect

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service